ENDEAVOR LIFE SCIENCE VENTURE FUNDS AND VENTURE STUDIO
Gershon Capital is a Swiss healthcare venture fund and hedge fund established in 2009, Emergent Life Sciences Fund with $3.15B AUM, that provides capital and strategic guidance for emerging life science companies that possess innovative technologies and strong commercial potential.
We leverage 20 years of experience in science, medicine, FDA/regulatory affairs, and industry to analyze companies at a highly technical level. This detailed analysis defines our due diligence process and gives syndicate investors a high level of confidence in our portfolio companies.
Our long standing relationships and professional affiliations with the most respected institutional investment funds, academic centers and industry leaders allows us to provide high level strategic consulting, technical advisory services, operational support, and cross boarder deal syndication.